AbbVie
ABBV
#25
Rank
NZ$685.00 B
Marketcap
NZ$387.58
Share price
0.98%
Change (1 day)
31.54%
Change (1 year)

The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โ€œABBVโ€.

Earnings for AbbVie (ABBV)

Earnings in 2025 (TTM): NZ$2.68 Billion

According to AbbVie's latest financial reports the company's current earnings are NZ$59.64 Billion. In 2024 the company made an earning of NZ$6.39 Billion a decrease over its 2023 earnings that were of NZ$10.75 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for AbbVie from 2011 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) NZ$2.68 B-57.97%
2024 NZ$6.39 B-40.54%
2023 NZ$10.75 B-53.62%
2022 NZ$23.19 B3.76%
2021 NZ$22.35 B282.25%
2020 NZ$5.84 B-59.67%
2019 NZ$14.50 B62.13%
2018 NZ$8.94 B-32.74%
2017 NZ$13.29 B-1.99%
2016 NZ$13.56 B18.65%
2015 NZ$11.43 B180.5%
2014 NZ$4.07 B-55.57%
2013 NZ$9.17 B-6.86%
2012 NZ$9.85 B56.05%
2011 NZ$6.31 B

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Pfizer
PFE
NZ$20.39 B 613.98%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$13.82 B 383.92%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$38.73 B 1,255.64%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$14.18 B 396.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
NZ$17.01 B 495.54%๐Ÿ‡บ๐Ÿ‡ธ USA
Biogen
BIIB
NZ$3.27 B 14.70%๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
NZ$16.04 B 461.62%๐Ÿ‡ฌ๐Ÿ‡ง UK
AstraZeneca
AZN
NZ$22.53 B 688.55%๐Ÿ‡ฌ๐Ÿ‡ง UK
Neurocrine Biosciences
NBIX
NZ$1.00 B-64.87%๐Ÿ‡บ๐Ÿ‡ธ USA